Business Wire

CA-XX-NETWORK

Share
Private Messaging App Launches on Quantum Resistant, Decentralized xx network

The world’s first quantum-resistant messaging app, xx messenger , launched on the xx network today. xx messenger allows users to communicate in real time through hundreds of decentralized nodes operating worldwide. The app is available for download on IOS and Android, features group chat as well as photo and audio sharing, and designed for easy use and switching to from legacy messaging apps.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005773/en/

Unlike existing messaging apps, xx messenger uses quantum-resistant cryptography to protect message content from decoding and cMix software to obfuscate or shred metadata—information about who sends, when they send, where they send from, and who receives. Randomly selected teams of xx nodes encrypt anonymity sets of 1,000 messages, which are then repeatedly shuffled and have also been encrypted using quantum-resistant cryptography. Information that links senders and receivers is destroyed, preventing third parties from tracking intimate details about the patterns and structure of our lives.

Centralized service providers now surveil and profile the majority of digital users. Our personal information has been marketed, auctioned, and monetized in an ever-increasingly exploitative manner to advertisers and political groups, which use it to micro-target and manipulate consumers or voters. Decentralized platforms offer a unique opportunity to weave the privacy principles of the early internet back into the fabric of the emerging web3 ecosystem. xx messenger is dedicated to protecting and strengthening inalienable privacy rights at the dawn of web3.

  • Existing Message Encryption is not Quantum Resistant: There is general agreement that, within the relevant timeframe, quantum computers will be able to decode communications that have been encrypted using legacy crypto. At that point, messages sent on all other existing messengers, even those with “strong end-to-end encryption,” will be easily retroactively decoded and analyzed by artificial intelligence. Only what has been said using xx messenger will remain private.
  • Only xx Offers Metadata Shredding: All existing mainstream messengers can capture and potentially exploit metadata. Metadata shredding works by sending messages through randomly chosen xx network nodes around the world. Each node changes the order and the encryption before forwarding and then erases any record of what it has done. Each part of the metadata about who is talking to whom is thereby destroyed before any of the parts can even be assembled to trace.
  • Full xx Decentralization: Every message sent on xx messenger travels through five nodes chosen at random from hundreds of xx nodes around the world. There is no centralized entity for governments to coerce, no company to insert spyware or reveal data from its database. The xx network supporting the xx messenger is a distributed, decentralized blockchain, now in mainnet, and is operated on transparent software run by more than 350 independently owned nodes in more than 80 countries. The xx messenger App, is truly a decentralized App (dApp), which means that it operates on a decentralized blockchain autonomously through smart contracts.

The pioneering team behind the creation of the xx messenger developed early practical, anonymous, and verifiable cryptographic systems and is led by renowned cryptographer David Chaum, who proposed and deployed digital currencies, mix networks, permissionless cryptographic solutions, and verifiable voting systems starting in the 1980s.

“Recent privacy concerns have sensitized the public to problems with control of personal information by centralized entities like Facebook. Realizing that their information is being misused by corporate entities, people are now trying to understand how to use cryptography and smartphones to protect themselves and change society in beneficial ways; xx messenger is securely decentralizing private communication the way Bitcoin decentralized finance. Let’s do this right: let’s take control of our own information– and our destiny.” said David Chaum, inventor of electronic cash and founder of xx network.

The xx messenger is available for download on Android and Apple app stores. Please follow us on Twitter and join our Telegram and Discord .

About xx network
xx network is a new type of platform, offering a protected digital sphere through which its users can share ideas and exchange value in a secure and private way. The xx network blockchain relies on a novel quantum-secure consensus algorithm that efficiently achieves linear authenticator complexity and single-block finality, ensuring scaleable consensus-based operations. The network was built by teams led by David Chaum, the Godfather of cryptocurrency.

For more information, please visit https://xx.network/ .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release

Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through

Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release

Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release

Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye